Principal Additive Manufacturing Engineer

Arthritis Foundation and founding sponsor Zimmer Biomet announce new community celebrating life after joint replacement and inspiring others to act on severe joint pain. Oct 26, 2026, 10:21 ET The Comeback Club connects people who have had joint replacement with those considering it. ATLANTA and WARSAW, Ind., Oct. 26, 2026 /PRNewswire/ - The Arthritis Foundation today announced the launch of the Comeback Club, a new community for people who have undergone joint replacement and for those who are considering it. With founding sponsorship from Zimmer Biomet, the Comeback Club will celebrate people who have undergone joint surgery and are getting back to the people, places and activities they love with less pain. Hearing from others who have experienced joint pain and have been through joint replacement is a powerful source of inspiration for people living with severe joint pain, and it can give them the urge they need to talk to a doctor and discuss treatment options. The Comeback Club builds on that insight and on the Arthritis Foundation's long history of providing community, connections and resources to the arthritis community. "The decision to have joint replacement surgery is not made lightly. It's also a deeply personal choice, and surgery may not be the right path for everyone. For those who have made that journey, and for those weighing it, the Comeback Club is a chance to celebrate and learn from others who have reclaimed their lives from chronic joint pain. Like our Live Yes! Connect Groups, the Comeback Club brings together people from different walks of life who share arthritis and all that comes with it," says Vickie Fung, Chief Strategy and Mission Officer, Arthritis Foundation. Comeback Club members will: * Celebrate each other's successes * Share their inspiring stories * Learn first-hand about joint replacement * Develop a better understanding of life before and after joint replacement By spotlighting those who have successfully navigated joint replacement surgery, the Comeback Club aims to offer real stories of hope and recovery that inspire others to take the next step toward relief. "Osteoarthritis affects nearly 600 million people worldwide and can shape how people live, move and engage with the world around them. As a global leader in innovative hip and knee replacement technologies, Zimmer Biomet is proud to partner with the Arthritis Foundation as the founding sponsor of the Comeback Club. This new community connects people who have undergone joint replacement with others exploring their treatment options, giving them a place to share experiences and learn from one another. We hope these authentic stories of renewed mobility and what may be possible after treatment will inspire more people to talk with their doctor and take the first step toward a comeback of their own," says Kristen Cardillo, SVP, Chief Communications Officer, Zimmer Biomet. The Comeback Club will launch at Arthritis Foundation Jingle Bell Run(R) events in Minneapolis, Minn. (Nov. 22); Seattle (Dec. 13) and Bellingham, Wash. (Dec. 12); Orange County, Calif. (Dec. 5) and Kansas City, Mo. (Dec. 6). Anyone who has had a joint replacement, or is thinking about one, is invited to join the Comeback Club and become part of the community. To learn more or sign up, visit www.arthritis.org/comebackclub. About the Arthritis Foundation The Arthritis Foundation is the leading nonprofit organization dedicated to the fight against arthritis - the nation's #1 cause of disability. Through groundbreaking scientific research, patient-centered programs, advocacy at all levels of government and robust community engagement, the Foundation empowers people to live their best lives while relentlessly pursuing a cure. With a presence in communities nationwide, we amplify the voices of those affected and work to drive lasting change. Learn more at arthritis.org and follow @arthritisfoundation on social media. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

Building the digital foundation for the next generation of manufacturing at Zimmer Biomet. Driving innovation in orthopedic manufacturing. In the medical technology industry, delivering consistent quality, precision, and traceability is essential. As a global leader in orthopedic innovation, Zimmer Biomet continuously invests in technologies that help its teams operate more efficiently, make informed decisions faster, and support the production of life-changing solutions for patients around the world. To further advance its manufacturing strategy, Zimmer Biomet embarked on a digital transformation initiative centered on Manufacturing Execution Systems (MES). Through a thoughtful, phased implementation approach and strong collaboration between operations, IT, and shop floor teams, the company established a connected digital foundation that is enhancing visibility, improving operational performance, and enabling future innovation. A people-first approach to digital transformation. Rather than pursuing a large-scale deployment all at once, Zimmer Biomet implemented MES one department at a time, prioritizing areas based on business impact and opportunities for value creation. This approach allowed teams to learn from each deployment, gather feedback directly from shop floor personnel, and continuously refine the experience before expanding across the organization. By placing employees at the center of the transformation, the company ensured that technology adoption aligned closely with day-to-day operational needs while creating momentum for long-term success. Siemens AG deployed MES in one department at a time based on the priority and impact of the business. Taking that phased approach was really helpful to understand feedback from its shop floor team members to improve its MES system for the next deployment." - Palak Shah, AMS Manager, Zimmer Biomet Connecting teams, data, and operations. A key factor in the success of the initiative was the strong partnership between IT and operations. Before launching MES, Zimmer Biomet established clear ownership between information technology (IT) and operational technology (OT) teams. IT focused on application management while OT teams owned MES operations and manufacturing support. This collaborative model streamlined communication, accelerated issue resolution, and provided a strong framework for scaling digital manufacturing initiatives across the business. By aligning people, processes, and technology, Zimmer Biomet created an environment where digital innovation could be adopted efficiently and sustainably. Unlocking real-time visibility across the shop floor. As Zimmer Biomet expanded its digital manufacturing capabilities, real-time operational visibility became a significant advantage. Today, MES provides teams with immediate access to critical information across production operations, including work-in-progress status, order priorities, quality insights, production performance metrics, and operational trends. With a unified view of manufacturing activities, employees can make informed decisions faster, maintain production flow, and proactively identify opportunities to improve both efficiency and quality. The result is a more connected manufacturing environment where data is accessible when and where it is needed. Transforming traceability and Quality Management. In an industry where quality and compliance are paramount, rapid access to accurate production information is essential. By digitizing manufacturing data within Opcenter MES, Zimmer Biomet has enhanced its ability to investigate operational and quality-related events with greater speed and confidence. Information that once required significant manual effort to compile can now be accessed almost instantly, enabling teams to quickly assess situations and take action while maintaining the highest standards of quality and patient safety. Traceability is the key feature in terms of scoping for quality or operational issues. It used to take a lot of effort, but because of all the digital data in Opcenter MES, now Siemens AG is able to scope all the issues within a few seconds." - Palak Shah, AMS Manager, Zimmer Biomet This enhanced traceability not only supports regulatory requirements but also provides valuable insights that help drive continuous improvement across manufacturing operations. Delivering measurable business results. The impact of Zimmer Biomet's MES transformation extends well beyond technology implementation. The initiative has delivered measurable business outcomes, including: * More than 90% reduction in non-conformance events * Improved direct labor efficiency * Enhanced operational visibility * Faster issue identification and resolution * Greater consistency across manufacturing processes These results demonstrate the value of combining digital technologies with a disciplined implementation strategy focused on operational excellence and continuous improvement. Creating the foundation for advanced manufacturing. Perhaps the most significant outcome of the MES initiative has been the creation of a robust digital backbone for future innovation. Today, MES serves as a central platform connecting automation technologies, ERP systems, Quality Management Systems (QMS), and other shop floor applications into a cohesive manufacturing ecosystem. Operators can manage their work through a unified environment, from understanding production priorities and executing work orders to collecting quality data and completing production activities. This seamless flow of information enables teams to focus more on value-added work while leveraging trusted manufacturing data throughout the production lifecycle. Looking ahead: the next phase of digital manufacturing. Zimmer Biomet continues to build on this momentum. As part of its advanced manufacturing roadmap, the company is upgrading to the latest MES version and plans to leverage capabilities such as Statistical Process Control (SPC), Advanced Planning and Scheduling (APS), and Mendix integration to create new digital tools for shop floor teams. These initiatives are designed to further digitalize manufacturing operations, expand access to actionable insights, and empower employees with the information needed to optimize performance and support continuous innovation. A blueprint for manufacturing excellence. Zimmer Biomet's MES journey illustrates how manufacturing leaders can unlock new levels of performance by thoughtfully connecting people, processes, and technology. The results achieved to date demonstrate more than a successful technology deployment. They reflect a long-term commitment to innovation, operational excellence, and continuous improvement. As the company continues to invest in advanced manufacturing capabilities, it is helping define what the future of digital manufacturing looks like in the medical technology industry, proving that digital transformation is most powerful when it empowers people, strengthens processes, and creates a platform for sustained innovation.

Zimmer Biomet (NYSE:ZBH) earns buy rating from Argus. Updated October 23, 2026 Key points. * Argus reiterated its "buy" rating on Zimmer Biomet and set a $125 price target, implying approximately 26.7% upside from the reported share price of $98.65. * Analyst sentiment remains mixed: seven analysts rate the stock a buy, 15 rate it a hold, and one rates it a sell, resulting in a consensus "hold" rating and a $104.47 price target. * Zimmer Biomet exceeded quarterly expectations, reporting $2.07 in earnings per share versus a $2.01 estimate and $2.18 billion in revenue versus a $2.13 billion estimate; revenue increased 4.8% year over year. * Tracking Zimmer Biomet through earnings season? MarketBeat All Access sends real-time alerts on ratings, earnings, and news - $149 a year, locked in for as long as you stay. Zimmer Biomet (NYSE:ZBH - Get Free Report)'s stock had its "buy" rating reiterated by Argus in a report released on Thursday, Benzinga reports. They presently have a $125.00 price target on the medical equipment provider's stock. Argus's price target would indicate a potential upside of 26.71% from the stock's current price. ZBH has been the subject of several other reports. Stifel Nicolaus lifted their target price on Zimmer Biomet from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. BMO Capital Markets restated a "market perform" rating on shares of Zimmer Biomet in a report on Monday, September 28th. Wall Street Zen downgraded Zimmer Biomet from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Canaccord Genuity Group raised their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a report on Monday, August 10th. Finally, Sanford C. Bernstein raised their price objective on Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $104.47. Zimmer Biomet trading down 0.2%. Shares of ZBH stock traded down $0.16 during trading hours on Thursday, reaching $98.65. 2,016,767 shares of the stock were exchanged, compared to its average volume of 2,231,348. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $104.15. The firm has a market capitalization of $18.82 billion, a price-to-earnings ratio of 24.00, a price-to-earnings-growth ratio of 1.79 and a beta of 0.49. The company's 50-day moving average price is $95.13 and its 200-day moving average price is $91.52. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the company earned $2.07 earnings per share. The business's revenue for the quarter was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities analysts anticipate that Zimmer Biomet will post 8.54 earnings per share for the current year. Insiders place their bets. In other news, insider Kevin R. Thornal sold 5,691 shares of the business's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Chad F. Phipps sold 3,000 shares of the business's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by insiders. Institutional trading of Zimmer Biomet. Several institutional investors and hedge funds have recently bought and sold shares of ZBH. Tacita Capital Inc purchased a new stake in Zimmer Biomet in the second quarter valued at $26,000. Ancora Advisors LLC purchased a new position in Zimmer Biomet in the 2nd quarter valued at about $29,000. Elevation Wealth Partners LLC raised its stake in Zimmer Biomet by 145.9% in the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 229 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zimmer Biomet in the first quarter valued at about $44,000. Finally, Parvin Asset Management LLC acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $47,000. 88.89% of the stock is currently owned by institutional investors and hedge funds. About Zimmer Biomet. Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures. The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments. Before you consider Zimmer Biomet, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list. While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power. Continue following MarketBeat